Holen Sie sich die Stockscreener-App
246.80
1.57%
-3.93
Schlusskurs vom Vortag:
$250.73
Offen:
$245
24-Stunden-Volumen:
623.47K
Relative Volume:
0.82
Marktkapitalisierung:
$17.94B
Einnahmen:
$1.98B
Nettoeinkommen (Verlust:
$420.90M
KGV:
42.26
EPS:
5.84
Netto-Cashflow:
$218.20M
1W Leistung:
-1.86%
1M Leistung:
-5.67%
6M Leistung:
+7.71%
1J Leistung:
+48.44%
1-Tages-Spanne:
$234.22
$248.96
1-Wochen-Bereich:
$234.22
$258.00
52-Wochen-Spanne:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
246.80 | 17.94B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Study Data Show Significant Glycemic Improvements With Omnipod 5 - Medical Product Outsourcing
RBC Cuts Price Target on Insulet to $325 From $340, Keeps Outperform Rating - marketscreener.com
What's Driving the Market Sentiment Around Insulet? - Benzinga
Insulet Announces Proposal for Upcoming Financing Deals - The Healthcare Technology Report.
Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insider Sell: Insulet - marketscreener.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? - Nasdaq
Insulet's Market Expansion: The Omnipod Impact on Diabetes Care - marketscreener.com
Insulet's $389 Million Trading Day Lands 450th in Market Rankings - AInvest
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ - Medical Design & Outsourcing
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - MSN
MedTechVets Announces Veteran Placement Partnership with Insulet - WebWire
GE Vernova, Insulet lead modest stock rebound amid tariff volatility - The Business Journals
Automated Insulin Delivery Systems - Trend Hunter
Insulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7% - Yahoo Finance
Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above - The Malaysian Reserve
Citigroup Adjusts Insulet Price Target to $315 From $355, Maintains Buy Rating - marketscreener.com
Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet? - simplywall.st
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Insulin Tech Leader Insulet Readies Q1 2025 Results: What's Next for Omnipod Maker? - Stock Titan
(PODD) Trading Advice - news.stocktradersdaily.com
Insulet Stock: Is PODD Outperforming the Healthcare Sector? - Nasdaq
Insulet Stock: Is PODD Outperforming The Healthcare Sector? - Barchart.com
New Age Alpha Advisors LLC Buys Shares of 30,096 Insulet Co. (NASDAQ:PODD) - MarketBeat
3 Reasons Investors Love Insulet (PODD) - Yahoo Finance
Insulet director Frederick Wayne sells $501,875 in stock By Investing.com - Investing.com Canada
Insulet director Frederick Wayne sells $501,875 in stock - Investing.com
Insulet glows with RADIANT results, CGMs becoming T2D standard - BioWorld MedTech
Insulet Gains 62.9% in a Year: What's Driving the Stock? - Yahoo
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5% - Yahoo Finance
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corp issues $450 million in senior notes By Investing.com - Investing.com Canada
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus
PODD Stock Gains Following the Launch of Omnipod 5 in Australia - Yahoo Finance
Insulet Corp issues $450 million in senior notes - Investing.com India
Insulet Closes $450 Million Senior Notes Issuance - TipRanks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers - Yahoo Finance
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 - Nasdaq
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day - TradingView
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - BioSpace
Insulet's RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition - Nasdaq
Omnipod 5 improves diabetes control in clinical trial By Investing.com - Investing.com South Africa
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Lelezard
Insulet says data shows significant glycemic improvement with Omnipod 5 - Seeking Alpha
Insulet Reports Glycemic Improvements With Omnipod Automated Insulin Delivery System - Marketscreener.com
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.01%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):